The Mission Report

OneMedForum 2013 Conference
Sir Francis Drake Hotel - January 7th - 9th, 2013

The 6th Annual OneMedForum is a gathering of leading investors and management of some of the most promising emerging life science companies in Asia and North America. Through panels, workshops and up-close programming with top industry leaders, attendees explore strategies for company growth finance with healthcare investors looking for outsized returns.

Advaxis, Inc. (ADXS)

Advaxis, Inc. (OTCBB: ADXS) is a leading clinical-stage biotechnology company engaged in developing next-generation immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the human immune response from the bacterium to the cancer itself. The company’s lead construct, ADXS-HPV, was named “Best Therapeutic Vaccine (approved or in development)” at the 2012 Vaccine Industry Excellence (ViE) Awards. For more information, visit the company’s Web site at

ADVENTRX Pharmaceuticals, Inc. (ANX)

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) is a biopharmaceutical company engaged in the development of proprietary product candidates for treating various diseases and conditions. ANX-188, the company’s lead product candidate, is initially being developed as a treatment for complications arising from sickle cell disease and has the potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in various serious and life-threatening diseases and conditions. For more information, visit the company’s Web site at

Agenus, Inc. (AGEN)

Agenus, Inc. (NASDAQ: AGEN) is a biotechnology company engaged in developing treatments for cancers and infectious diseases. The company’s focus is on immunotherapeutic products based on strong platform technologies, with multiple product candidates advancing through the clinic, including a number of product candidates that have advanced into late-stage clinical trials through corporate partners. For more information, visit the company’s Web site at

Amarantus Bioscience, Inc. (AMBS)

Amarantus Bioscience, Inc. (OTCQB: AMBS) is a development-stage biotechnology company focused on developing certain biologics surrounding its intellectual property and proprietary technologies for treating and/or diagnosing Parkinson’s disease, traumatic brain injury and other human diseases. Amarantus owns the intellectual property rights to Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), a therapeutic protein, and is developing MANF-based products as treatments for brain disorders. The company is additionally a founding member of the Coalition for Concussion Treatment. For more information, visit the company’s Web site at

Atossa Genetics, Inc. (ATOS)

Atossa Genetics, Inc. (NASDAQ: ATOS), known as The Breast Health Company, is engaged in the prevention of breast cancer through commercializing patented, FDA-approved diagnostic medical devices and patented, laboratory-developed tests for detecting precursors to breast cancer up to eight years before mammography. The company is also focused on research and development that will enable the commercialization of treatments for pre-cancerous lesions. Atossa Genetics is based in Seattle, Wash. For more information, visit the company’s Web site at

Bacterin International Holdings, Inc. (BONE)

Bacterin International Holdings, Inc. (NYSE MKT: BONE) is a developer, manufacturer and marketer of biologics products to domestic and international markets. The company’s proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold – promoting bone, subchondral repair and dermal growth. Bacterin’s medical device division develops, employs and licenses bioactive coatings for a variety of medical device applications. For more information, visit the company’s Web site at

BioLife Solutions, Inc. (BLFS)

BioLife Solutions, Inc. (OTCBB: BLFS) is a leading developer, manufacturer and marketer of patented hypothermic storage and cryopreservation solutions for cells and tissues. The company markets its proprietary HypoThermosol and CryoStor solutions to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery and toxicology testing. The company’s products are serum-free and protein-free, fully defined and formulated to reduce preservation-induced, delayed-onset cell damage and death. For more information, visit the company’s Web site at

CardioComm Solutions, Inc. (EKGGF)

CardioComm Solutions, Inc. (OTC Markets: EKGGF) has been a provider of ECG management software solutions for 17 years. Utilizing an unmatched patented and proprietary technology and ECG signal viewer, as well as offering flexible open-ended workflow solutions, the company provides the right solution for use with most of the world’s cardiac event monitors, enabling the recording, transfer, viewing, analyzing and storing of EKGs over a global virtual healthcare network. For more information, visit the company’s Web site at

CollabRX, Inc. (CLRX)

CollabRX, Inc. (NASDAQ: CLRX) is a leader in cloud-based expert systems for informing healthcare decision-making. Beginning with the area of greatest need, which is advanced cancer in patients who have effectively exhausted the standard of care, the company uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the top cancer experts in the nation. For more information, visit the company’s Web site at

CytoSorbents Corporation (CTSO)

CytoSorbents Corporation (OTCBB: CTSO) is a therapeutic device company focused on critical care. The company uses blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. CytoSorbents’ purification technology is based on biocompatible, highly porous polymer beads that are able to actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. The company’s flagship product, CytoSorb, is approved in the European Union as a safe and effective cytokine filter. For more information, visit the company’s Web site at

DARA BioSciences, Inc. (DARA)

DARA BioSciences, Inc. (NASDAQ: DARA) is a specialty pharmaceutical company engaged in developing and commercializing oncology treatment and supportive care products. Through agreements with various entities, the company has comprehensive commercial coverage across the national oncology market. DARA is part of an integrated national network with yearly sales of more than $1 billion in cancer therapeutics, and its distribution network consists of more than 45,000 retail pharmacies, mail order pharmacies and long-term care facilities. For more information, visit the company’s Web site at

FluoroPharma Medical, Inc. (FPMI)

FluoroPharma Medical, Inc. (OTCQB: FPMI) is a biopharmaceutical company focused on discovering and developing proprietary PET imaging and products for the evaluation of cardiac disease at the cellular and molecular levels. With licensed technology from the Massachusetts General Hospital in Boston, the company’s focus is on enabling personalized medicine through precision diagnostics to help the medical community more accurately diagnose disease at the earliest stages. For more information, visit the company’s Web site at

Immunovaccine, Inc. (IMV)

Immunovaccine, Inc. (TSX-V: IMV) is a clinical-stage vaccine development company focused on the advancement of its patented DepoVax vaccine adjuvanting platform and product candidates for cancer therapy, infectious disease and animal health. Demonstrating safety and immunogenicity potential, Immunovaccine has advanced its platform technology and proprietary cancer vaccines into Phase I human clinical trials. The company is also advancing a broad infectious disease pipeline that includes vaccines for malaria, RSV and anthrax, and a collaborative anti-cocaine vaccine program. For more information, visit the company’s Web site at

IntelGenx Technology Corp. (IGX)

IntelGenx Technology Corp. (TSX-V: IGX) is a drug delivery company engaged in developing oral controlled-release products and novel rapidly disintegrating delivery systems. Using its unique multiple layer delivery system, the company provides zero-order release of active drugs in the gastrointestinal tract. The company has additionally developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity, based on its experience with rapidly disintegrating films. For more information, visit the company’s Web site at

Medtronic Neuromodulation (MDT)

Medtronic Neuromodulation (NYSE: MDT) is the second-oldest and fourth-largest business unit of Medtronic, Inc., the world’s leader in medical technology. Neuromodulation was formed as the company transferred its expertise in heart electrical stimulation for the treatment of diseases and conditions involving the nervous system. Neuromodulation’s products include neurostimulation systems and implantable drug delivery systems for chronic pain, common movement disorders and urologic and gastrointestinal disorders. For more information, visit the company’s Web site at

MiMedx Group, Inc. (MDXG)

MiMedx Group, Inc. (OTCBB: MDXG) is an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterial products and bioimplants that are processed from human amniotic membrane. The company’s mission is to provide physicians with products and tissues to help the body heal itself. MiMedx Group’s tissue technologies are processed from human amniotic membrane derived from donated placentas, which mothers delivering full-term Caesarean section births can choose to donate prior to their delivery. For more information, visit the company’s Web site at

NanoViricides, Inc. (NNVC)

NanoViricides, Inc. (OTCBB: NNVC) is a development-stage company engaged in creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide class of drug candidates is designed for the specific purpose of attacking and dismantling enveloped virus particles. NanoViricides is developing drugs against various viral diseases, including H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, oral and genital herpes (HSV), viral diseases of the eye, Ebola virus and others. For more information, visit the company’s Web site at

NeuroMetrix, Inc. (NURO)

NeuroMetrix, Inc. (NASDAQ: NURO) is an innovative medical device company focused on developing and marketing home use and point-of-care devices, associated consumables and support software for treating and managing diabetes and its complications. Nerve-related complications of diabetes, or diabetic neuropathies, affect more than 50 percent of diabetes sufferers and are a key focus of the company. Physicians and other clinicians in retail health settings use NeuroMetrix’s products to optimize patient care and reduce healthcare costs. For more information, visit the company’s Web site at

Oragenics, Inc. (OGEN)

Oragenics, Inc. (OTCQB: OGEN) is dedicated to becoming a global leader in probiotics for oral health in humans and pets and in novel antibiotics against infectious disease. The company is engaged in developing, marketing and selling proprietary probiotics under the brand names Evora and ProBiora, designed specifically for enhancing oral health for humans and pets. Oragenics has also established an exclusive worldwide channel collaboration for lantibiotics with Intrexon Corporation. For more information, visit the company’s Web site at

Oxygen Biotherapeutics, Inc. (OXBT)

Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) is a development stage biomedical company engaged in the development of oxygen-rich intravenous and topical products. Oxycyte, the company’s proprietary perfluorocarbon (PFC) therapeutic oxygen carrier, is currently in clinical and preclinical studies for intravenous delivery for various indications. Oxygen Biotherapeutics is also developing PFC-based creams and gels for topical skin delivery for dermatologic conditions and potentially for wound care, and the company has commercialized its Dermacyte skin care cosmetics line for the anti-aging market. For more information, visit the company’s Web site at

Pressure BioSciences, Inc. (PBIO)

Pressure BioSciences, Inc. (OTCQB: PBIO) is engaged in developing, marketing and selling proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (PCT), a patented, enabling technology platform with multiple applications in the life sciences sample preparation market. PCT controls bio-molecular interactions by using cycles of hydrostatic pressure between ambient and ultra-high levels. The company is currently focusing its efforts on the development and sale of PCT-enhanced sample preparation systems. For more information, visit the company’s Web site at

Response Biomedical Corp. (RPBIF)

Response Biomedical Corp. (OTCBB: RPBIF) is a developer, manufacturer and marketer of rapid onsite diagnostics tests for use with its RAMP platform for clinical and environmental applications. Representing a new paradigm in diagnostics, RAMP provides reliable laboratory-quality results in minutes and is ideally suited for both point-of-care testing and laboratory use. Consisting of a reader and single-use disposable test cartridges, RAMP can potentially be adapted to more than 250 medical and non-medical tests currently performed in laboratories. For more information, visit the company’s Web site at

Synthetic Biologics, Inc. (SYN)

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company developing product candidates for serious infections and diseases. The company is developing a biologic for preventing C. diff infection as well as a series of monoclonal antibodies (mAbs) for treating serious infectious diseases. In collaboration with Intrexon, Synthetic Biologics is developing a synthetic DNA-based therapy for treating pulmonary arterial hypertension (PAH). The company is also developing treatments for relapsing-remitting multiple sclerosis, cognitive dysfunction in MS and amyotrophic lateral sclerosis. For more information, visit the company’s Web site at

Targeted Medical Pharma, Inc. (TRGM)

Targeted Medical Pharma, Inc. (OTCBB: TRGM) is a specialty pharmaceutical company engaged in developing and distributing prescription medical foods to physicians and pharmacies in the U.S. and the Middle East. The company manufactures 10 proprietary prescription-only medical foods and 48 convenience packed kits that pair a medical food and a branded or generic pharmaceutical. These represent a novel approach to managing certain disease states without the harmful side effects of traditional, high-dose prescription drugs. For more information, visit the company’s Web site at

TNI BioTech, Inc. (TNIB)

TNI BioTech, Inc. (PINKSHEETS: TNIB) is a biotech company engaged in combating fatal diseases through activating and mobilizing the body’s immune system using the company’s patented immunotherapy. The company’s products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections like HIV/AIDS, chronic inflammatory diseases and autoimmune diseases. For more information, visit the company’s Web site at


For more frequent updates, follow us on Twitter!

Home     About Us     Blog     Investors     IR Services     Market Research     Partners     Contact     Disclaimer

© 2013 Mission Investor Relations. All rights reserved.
3645 Marketplace Blvd.   Suite 130-280   Atlanta, GA 30344   404-941-8975